Brief: Lundbeck's Abilify Maintena schizophrenia drug best in head-to-head study

Otsuka

03/11/2014 16:17

COPENHAGEN, Nov 3 (Reuters) - H Lundbeck A/S  LUN.CO  says: 
 
 ** A head-to-head study showed that patients treated with Lundbeeck's Abilify Maintena (aripiprazole once-monthly) demonstrated a statistically significant improvement on the primary endpoint, quality-of-life measure, compared to those treated with paliperidone palmitate  
 
 ** Discontinuations due to adverse events occurred in 10.8 percent of patients in the aripiprazole once-monthly group compared to 18.4 percent of patients in the paliperidone once-monthly group 
 
((Copenhagen newsroom, tel: +45 33969655, e-mail: 
copenhagen.newsroom@thomsonreuters.com)) 
 
Source text for Eikon:  ID:nCSE5yDw  ((For more news, double-click on  LUN.CO ))